Company profile for Abivax

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Abivax is mobilizing the body’s natural immune system machinery to treat patients with inflammatory diseases, viral infections and cancer.As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis and other inflammatory diseases (ABX464), HIV (ABX464), and liver cancer (ABX196). Our mission is to utilize Abivax’s drug develo...
Abivax is mobilizing the body’s natural immune system machinery to treat patients with inflammatory diseases, viral infections and cancer.As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis and other inflammatory diseases (ABX464), HIV (ABX464), and liver cancer (ABX196). Our mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
5, rue de la Baume 75008 Paris
Telephone
Telephone
+33 (0) 1 53 83 08 41
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/03/3179780/0/en/Abivax-Announces-Patient-Reported-Outcomes-Data-from-the-Phase-3-ABTECT-Induction-Trials-of-Obefazimod-Demonstrating-Significant-Improvements-in-Quality-of-Life-for-Patients-with-M.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/10/06/3161446/0/en/Abivax-Announces-Late-Breaking-Presentation-of-8-Week-ABTECT-Induction-Trial-Results-in-Participants-With-and-Without-Prior-Inadequate-Response-to-Advanced-Therapies.html

GLOBENEWSWIRE
06 Oct 2025

https://www.globenewswire.com/news-release/2025/10/05/3161328/0/en/Abivax-Announces-Late-Breaking-Presentation-of-8-Week-ABTECT-Trial-Results-with-Updated-Safety-Data.html

GLOBENEWSWIRE
05 Oct 2025

https://www.globenewswire.com/news-release/2025/09/29/3158107/0/en/Abivax-Announces-Acceptance-of-Additional-Late-Breaking-Abstract-from-the-ABTECT-Phase-3-Induction-Trials-to-be-Presented-at-2025-United-European-Gastroenterology-UEG-Meeting.html

GLOBENEWSWIRE
29 Sep 2025

https://www.globenewswire.com/news-release/2025/09/23/3155082/0/en/Abivax-Announces-Presentation-of-Late-Breaking-Abstract-for-Obefazimod-from-the-ABTECT-Phase-3-Induction-Trials-at-2025-United-European-Gastroenterology-UEG-Meeting.html

GLOBENEWSWIRE
23 Sep 2025

https://www.globenewswire.com/news-release/2025/09/12/3149337/0/en/Abivax-to-Join-CAC-Mid-60-and-SBF-120-Indices-Following-Euronext-Paris-Annual-Review.html

GLOBENEWSWIRE
12 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty